Literature DB >> 9243128

5-Aminosalicylic acid-associated renal tubular acidosis with decreased renal function in Crohn's disease.

J Hämling1, A Raedler, U Helmchen, S Schreiber.   

Abstract

The use of 5-aminosalicylic acid (5-ASA, mesalazine) in Crohn's disease is usually well tolerated. Nevertheless, the occasional occurrence of nephrotoxic side effects has been described in several case reports. We present the case of a 34-year-old female in whom chronic use of 5-ASA may have caused renal damage which manifested with tubular acidosis, severe weight loss, shortness of breath and fatigue. For 17 years the patient has suffered from Crohn's disease. She received sulfasalazine (3 g/day) for 12 years and was treated with resin-coated mesalazine (3 g/day) for the last 72 months. Onset of weight loss of 10 kg over a 6-month period, accompanied by progressive shortness of breath and fatigue, lead to a diagnosis of metabolic acidosis and renal bicarbonate loss due to damage to the tubular epithelium. Kidney biopsy demonstrated acute interstitial nephritis which may be related to 5-ASA.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9243128     DOI: 10.1159/000201459

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  7 in total

1.  Late onset interstitial nephritis associated with mesalazine treatment.

Authors:  J Popoola; A F Muller; L Pollock; P O'Donnell; P Carmichael; P Stevens
Journal:  BMJ       Date:  1998-09-19

2.  Acute tubular injury associated with mesalazine therapy in an adolescent girl with inflammatory bowel disease.

Authors:  Nuray Uslu; Hulya Demir; Inci Nur Saltik-Temizel; Rezan Topaloğlu; Figen Gürakan; Aysel Yüce
Journal:  Dig Dis Sci       Date:  2007-04-03       Impact factor: 3.199

3.  Comparison of the effect of mesalazine and sulfasalazine on laboratory parameters: a retrospective observational study.

Authors:  Hideki Masuda; Yasuo Takahashi; Yayoi Nishida; Satoshi Asai
Journal:  Eur J Clin Pharmacol       Date:  2012-05-01       Impact factor: 2.953

4.  Management of Perianal Crohn's Disease.

Authors:  Benjamin Person; Steven D Wexner
Journal:  Curr Treat Options Gastroenterol       Date:  2005-06

5.  Interstitial nephritis from mesalazine: case report and literature review.

Authors:  Lois J Arend; James E Springate
Journal:  Pediatr Nephrol       Date:  2004-03-09       Impact factor: 3.714

6.  Renal effects of long-term treatment with 5-aminosalicylic acid.

Authors:  H Patel; A Barr; K N Jeejeebhoy
Journal:  Can J Gastroenterol       Date:  2009-03       Impact factor: 3.522

Review 7.  5-ASA induced interstitial nephritis in patients with inflammatory bowel disease: a systematic review.

Authors:  James G Moss; Christopher M Parry; Richard C L Holt; Stephen J McWilliam
Journal:  Eur J Med Res       Date:  2022-04-29       Impact factor: 4.981

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.